Pluvicto is a “radioligand” therapy, a type of treatment in which radioactive materials are attached to drugs which are attracted to and stick to certain proteins found on tumor cells. This makes radiotherapy better at hunting down cancer cells, and less likely to harm normal, healthy cells in the body. Pluvicto works by detecting a protein called prostate-specific membrane antigen (PSMA), which is found in 80 to 90% of prostate cancers.
The Phase 3 VISION clinical trail, which involved 831 patients, 551 of whom received the treatment, showed that Pluvicto extends life by around five months in terminal cases. In the UK, it is estimated that around 3,500 men will benefit from this treatment every year.